Search research articles
Contact Us
Filters
Showing results (611-620 of 659) with videos related to
Page
of 66
Sort By:
Journal of Hematology & Oncology
|
November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias
Jayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
American Journal of Hematology
|
May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia
Courtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Haematologica
|
December 12, 2024
Clinical interrogation of <i>TP53</i> aberrations and its impact on survival in patients with myeloid neoplasms
Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, et al.
The Lancet. Haematology
|
December 15, 2018
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
Nicholas J Short, Hagop M Kantarjian, Sanam Loghavi, et al.
British Journal of Haematology
|
September 22, 2025
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia
Wei-Ying Jen, Guilin Tang, Eitan Kugler, et al.
Cancer
|
April 1, 2021
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors
Koji Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 27, 2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Courtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Cell
|
November 5, 2025
Disparate leukemia mutations converge on nuclear phase-separated condensates
Gandhar K Datar, Elmira Khabusheva, Archish Anand, et al.
Blood Cancer Journal
|
April 2, 2025
VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial
Mahesh Swaminathan, Courtney D DiNardo, Abhishek Maiti, et al.
Blood Cancer Journal
|
February 10, 2021
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
Abhishek Maiti, Courtney D DiNardo, Naval G Daver, et al.
Page
of 66
Search research articles
Search
Showing results (611-620 of 659) with videos related to
Sort By:
Page
of 66
Journal of Hematology & Oncology
|
November 28, 2025
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias
Jayastu Senapati, Marina Konopleva, Ghayas C Issa, et al.
American Journal of Hematology
|
May 18, 2022
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia
Courtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Haematologica
|
December 12, 2024
Clinical interrogation of <i>TP53</i> aberrations and its impact on survival in patients with myeloid neoplasms
Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, et al.
The Lancet. Haematology
|
December 15, 2018
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
Nicholas J Short, Hagop M Kantarjian, Sanam Loghavi, et al.
British Journal of Haematology
|
September 22, 2025
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia
Wei-Ying Jen, Guilin Tang, Eitan Kugler, et al.
Cancer
|
April 1, 2021
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors
Koji Sasaki, Hagop M Kantarjian, Nicholas J Short, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 27, 2021
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Courtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, et al.
Cell
|
November 5, 2025
Disparate leukemia mutations converge on nuclear phase-separated condensates
Gandhar K Datar, Elmira Khabusheva, Archish Anand, et al.
Blood Cancer Journal
|
April 2, 2025
VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial
Mahesh Swaminathan, Courtney D DiNardo, Abhishek Maiti, et al.
Blood Cancer Journal
|
February 10, 2021
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
Abhishek Maiti, Courtney D DiNardo, Naval G Daver, et al.
Page
of 66